FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Venture-backed biotechs push into the clinic
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
Merck goes pivotal with acquired assets
A prostate cancer project licensed from Orion enters phase 3, while pivotal trials are expanded with assets originated at Kelun and Arqule.
Tango faces a fresh PRMT5 competitor
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
